mSphere-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2118912, encodeId=40cc21189129a, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：传染病 经验分享：审稿人很专业，杂志很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb791638292, createdName=平凡之路, createdTime=Sat Mar 11 11:27:19 CST 2023, time=2023-03-11, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1190756, encodeId=42f51190e56e2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：ASM的期刊，审稿比较快，发表的文章水平不低，编辑负责。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc7f6477604, createdName=ms4000001582217878, createdTime=Mon Feb 07 16:27:18 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106909, encodeId=66591106909f9, content=引言怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106910, encodeId=5eb911069100e, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584870, encodeId=149d5848e05b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投mSphere。去年10月份投出，拒稿，但给大修机会。今年2月10日修改后投出，等待中......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c58d1611556, createdName=liulaoshiyc, createdTime=Mon Feb 17 14:12:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861658, encodeId=daac86165817, content=植物病理学方向，两次小修已中，贴出时间线供大家参考，asm旗下的期刊，对于工作量的要求还是挺高的，偏重微生物方向。 01.29 manuscript submission 01.29 initial qc 01.31 with editor 01.31 reviewing editor assigned 01.31 under review 02.29 minor modifications 04.27 revision received 04.27 initial qc 04.27 with editor 04.30 reviewing editor assigned 04.30 under review 05.22 minor modifications 05.26 revision received 05.26 initial qc 05.26 with editor 05.27 reviewing editor assigned 05.27 under review 06.09 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Jun 09 23:33:54 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576206, encodeId=7f335e620632, content=审稿速度:1.0 经验分享：投稿一个月拒稿但允许重投打算修改后再次重投祝我好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/x3zaA8ibdNOzl5C5ot3vmRP7fhvtMIibLLQ1roy9Vc9rybhichx5Z9ggtuJrtYa7nepc0dhpTibQLo8R55z0T0bEnQ/0, createdBy=985d2236237, createdName=小迎迎, createdTime=Wed Sep 11 00:00:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853511, encodeId=65ce853511f7, content=审稿速度:1.0 经验分享：这个杂志我投过，特点是审稿快，不拖拉。有两种审稿方式，一是直接投，15天左右给审稿结果，如果接收可能会让小修，如果大改或补实验就会先把你据掉，允许再投，同样是15天内给结果。二是，你的手稿已经投过其它杂志，你把其它杂志的审稿意见以及你的修改一起提交，一般5天内好像就能给结果。我是第一种，先是被拒了，要求补数据，及进行修改，补完后又投，15天左右就给就接收了。所以，这个杂志审稿快并不是水，而是加快了审稿速度，节省了作者很多时间。置于质量，msphere 是asm旗下期刊，应该不会错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Sat Aug 31 17:11:46 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566156, encodeId=48cf566156e3, content=问一下这个杂志的分区是几区，还有以前的clinical andvaccine immunology是三区，但是杂志没有了，改成投在mSphere上，那现在是几区啊？整懵了scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, beContent=scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52f2182755, createdName=12078463m83(暂无昵称), createdTime=Fri Jan 25 00:00:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547406, encodeId=b1c954e406f2, content=美国微生物协会刚创办期刊，认可度可想而知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c971931559, createdName=scihappier, createdTime=Tue Sep 19 22:17:00 CST 2017, time=2017-09-19, status=1, ipAttribution=)]

2023-03-11 平凡之路来自河南省

审稿速度:3.0 | 投稿命中率:25.0
偏重的研究方向：传染病
经验分享：审稿人很专业，杂志很不错

82 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2118912, encodeId=40cc21189129a, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：传染病 经验分享：审稿人很专业，杂志很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb791638292, createdName=平凡之路, createdTime=Sat Mar 11 11:27:19 CST 2023, time=2023-03-11, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1190756, encodeId=42f51190e56e2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：ASM的期刊，审稿比较快，发表的文章水平不低，编辑负责。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc7f6477604, createdName=ms4000001582217878, createdTime=Mon Feb 07 16:27:18 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106909, encodeId=66591106909f9, content=引言怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106910, encodeId=5eb911069100e, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584870, encodeId=149d5848e05b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投mSphere。去年10月份投出，拒稿，但给大修机会。今年2月10日修改后投出，等待中......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c58d1611556, createdName=liulaoshiyc, createdTime=Mon Feb 17 14:12:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861658, encodeId=daac86165817, content=植物病理学方向，两次小修已中，贴出时间线供大家参考，asm旗下的期刊，对于工作量的要求还是挺高的，偏重微生物方向。 01.29 manuscript submission 01.29 initial qc 01.31 with editor 01.31 reviewing editor assigned 01.31 under review 02.29 minor modifications 04.27 revision received 04.27 initial qc 04.27 with editor 04.30 reviewing editor assigned 04.30 under review 05.22 minor modifications 05.26 revision received 05.26 initial qc 05.26 with editor 05.27 reviewing editor assigned 05.27 under review 06.09 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Jun 09 23:33:54 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576206, encodeId=7f335e620632, content=审稿速度:1.0 经验分享：投稿一个月拒稿但允许重投打算修改后再次重投祝我好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/x3zaA8ibdNOzl5C5ot3vmRP7fhvtMIibLLQ1roy9Vc9rybhichx5Z9ggtuJrtYa7nepc0dhpTibQLo8R55z0T0bEnQ/0, createdBy=985d2236237, createdName=小迎迎, createdTime=Wed Sep 11 00:00:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853511, encodeId=65ce853511f7, content=审稿速度:1.0 经验分享：这个杂志我投过，特点是审稿快，不拖拉。有两种审稿方式，一是直接投，15天左右给审稿结果，如果接收可能会让小修，如果大改或补实验就会先把你据掉，允许再投，同样是15天内给结果。二是，你的手稿已经投过其它杂志，你把其它杂志的审稿意见以及你的修改一起提交，一般5天内好像就能给结果。我是第一种，先是被拒了，要求补数据，及进行修改，补完后又投，15天左右就给就接收了。所以，这个杂志审稿快并不是水，而是加快了审稿速度，节省了作者很多时间。置于质量，msphere 是asm旗下期刊，应该不会错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Sat Aug 31 17:11:46 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566156, encodeId=48cf566156e3, content=问一下这个杂志的分区是几区，还有以前的clinical andvaccine immunology是三区，但是杂志没有了，改成投在mSphere上，那现在是几区啊？整懵了scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, beContent=scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52f2182755, createdName=12078463m83(暂无昵称), createdTime=Fri Jan 25 00:00:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547406, encodeId=b1c954e406f2, content=美国微生物协会刚创办期刊，认可度可想而知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c971931559, createdName=scihappier, createdTime=Tue Sep 19 22:17:00 CST 2017, time=2017-09-19, status=1, ipAttribution=)]

2022-02-07 ms4000001582217878

审稿速度:1.0 | 投稿命中率:50.0
经验分享：ASM的期刊，审稿比较快，发表的文章水平不低，编辑负责。

99 0

[GetPortalCommentsPageByObjectIdResponse(id=2118912, encodeId=40cc21189129a, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：传染病 经验分享：审稿人很专业，杂志很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb791638292, createdName=平凡之路, createdTime=Sat Mar 11 11:27:19 CST 2023, time=2023-03-11, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1190756, encodeId=42f51190e56e2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：ASM的期刊，审稿比较快，发表的文章水平不低，编辑负责。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc7f6477604, createdName=ms4000001582217878, createdTime=Mon Feb 07 16:27:18 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106909, encodeId=66591106909f9, content=引言怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106910, encodeId=5eb911069100e, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584870, encodeId=149d5848e05b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投mSphere。去年10月份投出，拒稿，但给大修机会。今年2月10日修改后投出，等待中......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c58d1611556, createdName=liulaoshiyc, createdTime=Mon Feb 17 14:12:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861658, encodeId=daac86165817, content=植物病理学方向，两次小修已中，贴出时间线供大家参考，asm旗下的期刊，对于工作量的要求还是挺高的，偏重微生物方向。 01.29 manuscript submission 01.29 initial qc 01.31 with editor 01.31 reviewing editor assigned 01.31 under review 02.29 minor modifications 04.27 revision received 04.27 initial qc 04.27 with editor 04.30 reviewing editor assigned 04.30 under review 05.22 minor modifications 05.26 revision received 05.26 initial qc 05.26 with editor 05.27 reviewing editor assigned 05.27 under review 06.09 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Jun 09 23:33:54 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576206, encodeId=7f335e620632, content=审稿速度:1.0 经验分享：投稿一个月拒稿但允许重投打算修改后再次重投祝我好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/x3zaA8ibdNOzl5C5ot3vmRP7fhvtMIibLLQ1roy9Vc9rybhichx5Z9ggtuJrtYa7nepc0dhpTibQLo8R55z0T0bEnQ/0, createdBy=985d2236237, createdName=小迎迎, createdTime=Wed Sep 11 00:00:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853511, encodeId=65ce853511f7, content=审稿速度:1.0 经验分享：这个杂志我投过，特点是审稿快，不拖拉。有两种审稿方式，一是直接投，15天左右给审稿结果，如果接收可能会让小修，如果大改或补实验就会先把你据掉，允许再投，同样是15天内给结果。二是，你的手稿已经投过其它杂志，你把其它杂志的审稿意见以及你的修改一起提交，一般5天内好像就能给结果。我是第一种，先是被拒了，要求补数据，及进行修改，补完后又投，15天左右就给就接收了。所以，这个杂志审稿快并不是水，而是加快了审稿速度，节省了作者很多时间。置于质量，msphere 是asm旗下期刊，应该不会错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Sat Aug 31 17:11:46 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566156, encodeId=48cf566156e3, content=问一下这个杂志的分区是几区，还有以前的clinical andvaccine immunology是三区，但是杂志没有了，改成投在mSphere上，那现在是几区啊？整懵了scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, beContent=scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52f2182755, createdName=12078463m83(暂无昵称), createdTime=Fri Jan 25 00:00:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547406, encodeId=b1c954e406f2, content=美国微生物协会刚创办期刊，认可度可想而知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c971931559, createdName=scihappier, createdTime=Tue Sep 19 22:17:00 CST 2017, time=2017-09-19, status=1, ipAttribution=)]

2021-12-27 小动量

引言怎么写？

113 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2118912, encodeId=40cc21189129a, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：传染病 经验分享：审稿人很专业，杂志很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb791638292, createdName=平凡之路, createdTime=Sat Mar 11 11:27:19 CST 2023, time=2023-03-11, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1190756, encodeId=42f51190e56e2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：ASM的期刊，审稿比较快，发表的文章水平不低，编辑负责。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc7f6477604, createdName=ms4000001582217878, createdTime=Mon Feb 07 16:27:18 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106909, encodeId=66591106909f9, content=引言怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106910, encodeId=5eb911069100e, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584870, encodeId=149d5848e05b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投mSphere。去年10月份投出，拒稿，但给大修机会。今年2月10日修改后投出，等待中......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c58d1611556, createdName=liulaoshiyc, createdTime=Mon Feb 17 14:12:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861658, encodeId=daac86165817, content=植物病理学方向，两次小修已中，贴出时间线供大家参考，asm旗下的期刊，对于工作量的要求还是挺高的，偏重微生物方向。 01.29 manuscript submission 01.29 initial qc 01.31 with editor 01.31 reviewing editor assigned 01.31 under review 02.29 minor modifications 04.27 revision received 04.27 initial qc 04.27 with editor 04.30 reviewing editor assigned 04.30 under review 05.22 minor modifications 05.26 revision received 05.26 initial qc 05.26 with editor 05.27 reviewing editor assigned 05.27 under review 06.09 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Jun 09 23:33:54 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576206, encodeId=7f335e620632, content=审稿速度:1.0 经验分享：投稿一个月拒稿但允许重投打算修改后再次重投祝我好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/x3zaA8ibdNOzl5C5ot3vmRP7fhvtMIibLLQ1roy9Vc9rybhichx5Z9ggtuJrtYa7nepc0dhpTibQLo8R55z0T0bEnQ/0, createdBy=985d2236237, createdName=小迎迎, createdTime=Wed Sep 11 00:00:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853511, encodeId=65ce853511f7, content=审稿速度:1.0 经验分享：这个杂志我投过，特点是审稿快，不拖拉。有两种审稿方式，一是直接投，15天左右给审稿结果，如果接收可能会让小修，如果大改或补实验就会先把你据掉，允许再投，同样是15天内给结果。二是，你的手稿已经投过其它杂志，你把其它杂志的审稿意见以及你的修改一起提交，一般5天内好像就能给结果。我是第一种，先是被拒了，要求补数据，及进行修改，补完后又投，15天左右就给就接收了。所以，这个杂志审稿快并不是水，而是加快了审稿速度，节省了作者很多时间。置于质量，msphere 是asm旗下期刊，应该不会错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Sat Aug 31 17:11:46 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566156, encodeId=48cf566156e3, content=问一下这个杂志的分区是几区，还有以前的clinical andvaccine immunology是三区，但是杂志没有了，改成投在mSphere上，那现在是几区啊？整懵了scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, beContent=scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52f2182755, createdName=12078463m83(暂无昵称), createdTime=Fri Jan 25 00:00:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547406, encodeId=b1c954e406f2, content=美国微生物协会刚创办期刊，认可度可想而知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c971931559, createdName=scihappier, createdTime=Tue Sep 19 22:17:00 CST 2017, time=2017-09-19, status=1, ipAttribution=)]

2021-12-27 msSSSSSD

引言一般分几段？

96 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2118912, encodeId=40cc21189129a, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：传染病 经验分享：审稿人很专业，杂志很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb791638292, createdName=平凡之路, createdTime=Sat Mar 11 11:27:19 CST 2023, time=2023-03-11, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1190756, encodeId=42f51190e56e2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：ASM的期刊，审稿比较快，发表的文章水平不低，编辑负责。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc7f6477604, createdName=ms4000001582217878, createdTime=Mon Feb 07 16:27:18 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106909, encodeId=66591106909f9, content=引言怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106910, encodeId=5eb911069100e, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584870, encodeId=149d5848e05b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投mSphere。去年10月份投出，拒稿，但给大修机会。今年2月10日修改后投出，等待中......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c58d1611556, createdName=liulaoshiyc, createdTime=Mon Feb 17 14:12:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861658, encodeId=daac86165817, content=植物病理学方向，两次小修已中，贴出时间线供大家参考，asm旗下的期刊，对于工作量的要求还是挺高的，偏重微生物方向。 01.29 manuscript submission 01.29 initial qc 01.31 with editor 01.31 reviewing editor assigned 01.31 under review 02.29 minor modifications 04.27 revision received 04.27 initial qc 04.27 with editor 04.30 reviewing editor assigned 04.30 under review 05.22 minor modifications 05.26 revision received 05.26 initial qc 05.26 with editor 05.27 reviewing editor assigned 05.27 under review 06.09 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Jun 09 23:33:54 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576206, encodeId=7f335e620632, content=审稿速度:1.0 经验分享：投稿一个月拒稿但允许重投打算修改后再次重投祝我好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/x3zaA8ibdNOzl5C5ot3vmRP7fhvtMIibLLQ1roy9Vc9rybhichx5Z9ggtuJrtYa7nepc0dhpTibQLo8R55z0T0bEnQ/0, createdBy=985d2236237, createdName=小迎迎, createdTime=Wed Sep 11 00:00:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853511, encodeId=65ce853511f7, content=审稿速度:1.0 经验分享：这个杂志我投过，特点是审稿快，不拖拉。有两种审稿方式，一是直接投，15天左右给审稿结果，如果接收可能会让小修，如果大改或补实验就会先把你据掉，允许再投，同样是15天内给结果。二是，你的手稿已经投过其它杂志，你把其它杂志的审稿意见以及你的修改一起提交，一般5天内好像就能给结果。我是第一种，先是被拒了，要求补数据，及进行修改，补完后又投，15天左右就给就接收了。所以，这个杂志审稿快并不是水，而是加快了审稿速度，节省了作者很多时间。置于质量，msphere 是asm旗下期刊，应该不会错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Sat Aug 31 17:11:46 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566156, encodeId=48cf566156e3, content=问一下这个杂志的分区是几区，还有以前的clinical andvaccine immunology是三区，但是杂志没有了，改成投在mSphere上，那现在是几区啊？整懵了scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, beContent=scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52f2182755, createdName=12078463m83(暂无昵称), createdTime=Fri Jan 25 00:00:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547406, encodeId=b1c954e406f2, content=美国微生物协会刚创办期刊，认可度可想而知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c971931559, createdName=scihappier, createdTime=Tue Sep 19 22:17:00 CST 2017, time=2017-09-19, status=1, ipAttribution=)]

2020-02-17 liulaoshiyc

审稿速度:2.0 | 投稿命中率:25.0
经验分享：第一次投mSphere。去年10月份投出，拒稿，但给大修机会。今年2月10日修改后投出，等待中.......

193 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2118912, encodeId=40cc21189129a, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：传染病 经验分享：审稿人很专业，杂志很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb791638292, createdName=平凡之路, createdTime=Sat Mar 11 11:27:19 CST 2023, time=2023-03-11, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1190756, encodeId=42f51190e56e2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：ASM的期刊，审稿比较快，发表的文章水平不低，编辑负责。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc7f6477604, createdName=ms4000001582217878, createdTime=Mon Feb 07 16:27:18 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106909, encodeId=66591106909f9, content=引言怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106910, encodeId=5eb911069100e, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584870, encodeId=149d5848e05b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投mSphere。去年10月份投出，拒稿，但给大修机会。今年2月10日修改后投出，等待中......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c58d1611556, createdName=liulaoshiyc, createdTime=Mon Feb 17 14:12:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861658, encodeId=daac86165817, content=植物病理学方向，两次小修已中，贴出时间线供大家参考，asm旗下的期刊，对于工作量的要求还是挺高的，偏重微生物方向。 01.29 manuscript submission 01.29 initial qc 01.31 with editor 01.31 reviewing editor assigned 01.31 under review 02.29 minor modifications 04.27 revision received 04.27 initial qc 04.27 with editor 04.30 reviewing editor assigned 04.30 under review 05.22 minor modifications 05.26 revision received 05.26 initial qc 05.26 with editor 05.27 reviewing editor assigned 05.27 under review 06.09 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Jun 09 23:33:54 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576206, encodeId=7f335e620632, content=审稿速度:1.0 经验分享：投稿一个月拒稿但允许重投打算修改后再次重投祝我好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/x3zaA8ibdNOzl5C5ot3vmRP7fhvtMIibLLQ1roy9Vc9rybhichx5Z9ggtuJrtYa7nepc0dhpTibQLo8R55z0T0bEnQ/0, createdBy=985d2236237, createdName=小迎迎, createdTime=Wed Sep 11 00:00:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853511, encodeId=65ce853511f7, content=审稿速度:1.0 经验分享：这个杂志我投过，特点是审稿快，不拖拉。有两种审稿方式，一是直接投，15天左右给审稿结果，如果接收可能会让小修，如果大改或补实验就会先把你据掉，允许再投，同样是15天内给结果。二是，你的手稿已经投过其它杂志，你把其它杂志的审稿意见以及你的修改一起提交，一般5天内好像就能给结果。我是第一种，先是被拒了，要求补数据，及进行修改，补完后又投，15天左右就给就接收了。所以，这个杂志审稿快并不是水，而是加快了审稿速度，节省了作者很多时间。置于质量，msphere 是asm旗下期刊，应该不会错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Sat Aug 31 17:11:46 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566156, encodeId=48cf566156e3, content=问一下这个杂志的分区是几区，还有以前的clinical andvaccine immunology是三区，但是杂志没有了，改成投在mSphere上，那现在是几区啊？整懵了scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, beContent=scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52f2182755, createdName=12078463m83(暂无昵称), createdTime=Fri Jan 25 00:00:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547406, encodeId=b1c954e406f2, content=美国微生物协会刚创办期刊，认可度可想而知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c971931559, createdName=scihappier, createdTime=Tue Sep 19 22:17:00 CST 2017, time=2017-09-19, status=1, ipAttribution=)]

2020-06-09 ms9526231670310936

植物病理学方向，两次小修已中，贴出时间线供大家参考，asm旗下的期刊，对于工作量的要求还是挺高的，偏重微生物方向。
01.29 manuscript submission
01.29 initial qc
01.31 with editor
01.31 reviewing editor assigned
01.31 under review
02.29 minor modifications
04.27 revision received
04.27 initial qc
04.27 with editor
04.30 reviewing editor assigned
04.30 under review
05.22 minor modifications
05.26 revision received
05.26 initial qc
05.26 with editor
05.27 reviewing editor assigned
05.27 under review
06.09 accepted

160 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2118912, encodeId=40cc21189129a, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：传染病 经验分享：审稿人很专业，杂志很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb791638292, createdName=平凡之路, createdTime=Sat Mar 11 11:27:19 CST 2023, time=2023-03-11, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1190756, encodeId=42f51190e56e2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：ASM的期刊，审稿比较快，发表的文章水平不低，编辑负责。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc7f6477604, createdName=ms4000001582217878, createdTime=Mon Feb 07 16:27:18 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106909, encodeId=66591106909f9, content=引言怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106910, encodeId=5eb911069100e, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584870, encodeId=149d5848e05b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投mSphere。去年10月份投出，拒稿，但给大修机会。今年2月10日修改后投出，等待中......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c58d1611556, createdName=liulaoshiyc, createdTime=Mon Feb 17 14:12:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861658, encodeId=daac86165817, content=植物病理学方向，两次小修已中，贴出时间线供大家参考，asm旗下的期刊，对于工作量的要求还是挺高的，偏重微生物方向。 01.29 manuscript submission 01.29 initial qc 01.31 with editor 01.31 reviewing editor assigned 01.31 under review 02.29 minor modifications 04.27 revision received 04.27 initial qc 04.27 with editor 04.30 reviewing editor assigned 04.30 under review 05.22 minor modifications 05.26 revision received 05.26 initial qc 05.26 with editor 05.27 reviewing editor assigned 05.27 under review 06.09 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Jun 09 23:33:54 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576206, encodeId=7f335e620632, content=审稿速度:1.0 经验分享：投稿一个月拒稿但允许重投打算修改后再次重投祝我好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/x3zaA8ibdNOzl5C5ot3vmRP7fhvtMIibLLQ1roy9Vc9rybhichx5Z9ggtuJrtYa7nepc0dhpTibQLo8R55z0T0bEnQ/0, createdBy=985d2236237, createdName=小迎迎, createdTime=Wed Sep 11 00:00:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853511, encodeId=65ce853511f7, content=审稿速度:1.0 经验分享：这个杂志我投过，特点是审稿快，不拖拉。有两种审稿方式，一是直接投，15天左右给审稿结果，如果接收可能会让小修，如果大改或补实验就会先把你据掉，允许再投，同样是15天内给结果。二是，你的手稿已经投过其它杂志，你把其它杂志的审稿意见以及你的修改一起提交，一般5天内好像就能给结果。我是第一种，先是被拒了，要求补数据，及进行修改，补完后又投，15天左右就给就接收了。所以，这个杂志审稿快并不是水，而是加快了审稿速度，节省了作者很多时间。置于质量，msphere 是asm旗下期刊，应该不会错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Sat Aug 31 17:11:46 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566156, encodeId=48cf566156e3, content=问一下这个杂志的分区是几区，还有以前的clinical andvaccine immunology是三区，但是杂志没有了，改成投在mSphere上，那现在是几区啊？整懵了scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, beContent=scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52f2182755, createdName=12078463m83(暂无昵称), createdTime=Fri Jan 25 00:00:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547406, encodeId=b1c954e406f2, content=美国微生物协会刚创办期刊，认可度可想而知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c971931559, createdName=scihappier, createdTime=Tue Sep 19 22:17:00 CST 2017, time=2017-09-19, status=1, ipAttribution=)]

2019-09-11 小迎迎

审稿速度:1.0
经验分享：投稿一个月拒稿但允许重投打算修改后再次重投祝我好运

187 0

[GetPortalCommentsPageByObjectIdResponse(id=2118912, encodeId=40cc21189129a, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：传染病 经验分享：审稿人很专业，杂志很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb791638292, createdName=平凡之路, createdTime=Sat Mar 11 11:27:19 CST 2023, time=2023-03-11, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1190756, encodeId=42f51190e56e2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：ASM的期刊，审稿比较快，发表的文章水平不低，编辑负责。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc7f6477604, createdName=ms4000001582217878, createdTime=Mon Feb 07 16:27:18 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106909, encodeId=66591106909f9, content=引言怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106910, encodeId=5eb911069100e, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584870, encodeId=149d5848e05b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投mSphere。去年10月份投出，拒稿，但给大修机会。今年2月10日修改后投出，等待中......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c58d1611556, createdName=liulaoshiyc, createdTime=Mon Feb 17 14:12:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861658, encodeId=daac86165817, content=植物病理学方向，两次小修已中，贴出时间线供大家参考，asm旗下的期刊，对于工作量的要求还是挺高的，偏重微生物方向。 01.29 manuscript submission 01.29 initial qc 01.31 with editor 01.31 reviewing editor assigned 01.31 under review 02.29 minor modifications 04.27 revision received 04.27 initial qc 04.27 with editor 04.30 reviewing editor assigned 04.30 under review 05.22 minor modifications 05.26 revision received 05.26 initial qc 05.26 with editor 05.27 reviewing editor assigned 05.27 under review 06.09 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Jun 09 23:33:54 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576206, encodeId=7f335e620632, content=审稿速度:1.0 经验分享：投稿一个月拒稿但允许重投打算修改后再次重投祝我好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/x3zaA8ibdNOzl5C5ot3vmRP7fhvtMIibLLQ1roy9Vc9rybhichx5Z9ggtuJrtYa7nepc0dhpTibQLo8R55z0T0bEnQ/0, createdBy=985d2236237, createdName=小迎迎, createdTime=Wed Sep 11 00:00:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853511, encodeId=65ce853511f7, content=审稿速度:1.0 经验分享：这个杂志我投过，特点是审稿快，不拖拉。有两种审稿方式，一是直接投，15天左右给审稿结果，如果接收可能会让小修，如果大改或补实验就会先把你据掉，允许再投，同样是15天内给结果。二是，你的手稿已经投过其它杂志，你把其它杂志的审稿意见以及你的修改一起提交，一般5天内好像就能给结果。我是第一种，先是被拒了，要求补数据，及进行修改，补完后又投，15天左右就给就接收了。所以，这个杂志审稿快并不是水，而是加快了审稿速度，节省了作者很多时间。置于质量，msphere 是asm旗下期刊，应该不会错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Sat Aug 31 17:11:46 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566156, encodeId=48cf566156e3, content=问一下这个杂志的分区是几区，还有以前的clinical andvaccine immunology是三区，但是杂志没有了，改成投在mSphere上，那现在是几区啊？整懵了scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, beContent=scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52f2182755, createdName=12078463m83(暂无昵称), createdTime=Fri Jan 25 00:00:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547406, encodeId=b1c954e406f2, content=美国微生物协会刚创办期刊，认可度可想而知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c971931559, createdName=scihappier, createdTime=Tue Sep 19 22:17:00 CST 2017, time=2017-09-19, status=1, ipAttribution=)]

2019-08-31 ms2983094698733738

审稿速度:1.0
经验分享：这个杂志我投过，特点是审稿快，不拖拉。有两种审稿方式，一是直接投，15天左右给审稿结果，如果接收可能会让小修，如果大改或补实验就会先把你据掉，允许再投，同样是15天内给结果。二是，你的手稿已经投过其它杂志，你把其它杂志的审稿意见以及你的修改一起提交，一般5天内好像就能给结果。我是第一种，先是被拒了，要求补数据，及进行修改，补完后又投，15天左右就给就接收了。所以，这个杂志审稿快并不是水，而是加快了审稿速度，节省了作者很多时间。置于质量，msphere 是asm旗下期刊，应该不会错。

351 0

[GetPortalCommentsPageByObjectIdResponse(id=2118912, encodeId=40cc21189129a, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：传染病 经验分享：审稿人很专业，杂志很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb791638292, createdName=平凡之路, createdTime=Sat Mar 11 11:27:19 CST 2023, time=2023-03-11, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1190756, encodeId=42f51190e56e2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：ASM的期刊，审稿比较快，发表的文章水平不低，编辑负责。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc7f6477604, createdName=ms4000001582217878, createdTime=Mon Feb 07 16:27:18 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106909, encodeId=66591106909f9, content=引言怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106910, encodeId=5eb911069100e, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584870, encodeId=149d5848e05b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投mSphere。去年10月份投出，拒稿，但给大修机会。今年2月10日修改后投出，等待中......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c58d1611556, createdName=liulaoshiyc, createdTime=Mon Feb 17 14:12:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861658, encodeId=daac86165817, content=植物病理学方向，两次小修已中，贴出时间线供大家参考，asm旗下的期刊，对于工作量的要求还是挺高的，偏重微生物方向。 01.29 manuscript submission 01.29 initial qc 01.31 with editor 01.31 reviewing editor assigned 01.31 under review 02.29 minor modifications 04.27 revision received 04.27 initial qc 04.27 with editor 04.30 reviewing editor assigned 04.30 under review 05.22 minor modifications 05.26 revision received 05.26 initial qc 05.26 with editor 05.27 reviewing editor assigned 05.27 under review 06.09 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Jun 09 23:33:54 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576206, encodeId=7f335e620632, content=审稿速度:1.0 经验分享：投稿一个月拒稿但允许重投打算修改后再次重投祝我好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/x3zaA8ibdNOzl5C5ot3vmRP7fhvtMIibLLQ1roy9Vc9rybhichx5Z9ggtuJrtYa7nepc0dhpTibQLo8R55z0T0bEnQ/0, createdBy=985d2236237, createdName=小迎迎, createdTime=Wed Sep 11 00:00:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853511, encodeId=65ce853511f7, content=审稿速度:1.0 经验分享：这个杂志我投过，特点是审稿快，不拖拉。有两种审稿方式，一是直接投，15天左右给审稿结果，如果接收可能会让小修，如果大改或补实验就会先把你据掉，允许再投，同样是15天内给结果。二是，你的手稿已经投过其它杂志，你把其它杂志的审稿意见以及你的修改一起提交，一般5天内好像就能给结果。我是第一种，先是被拒了，要求补数据，及进行修改，补完后又投，15天左右就给就接收了。所以，这个杂志审稿快并不是水，而是加快了审稿速度，节省了作者很多时间。置于质量，msphere 是asm旗下期刊，应该不会错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Sat Aug 31 17:11:46 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566156, encodeId=48cf566156e3, content=问一下这个杂志的分区是几区，还有以前的clinical andvaccine immunology是三区，但是杂志没有了，改成投在mSphere上，那现在是几区啊？整懵了scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, beContent=scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52f2182755, createdName=12078463m83(暂无昵称), createdTime=Fri Jan 25 00:00:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547406, encodeId=b1c954e406f2, content=美国微生物协会刚创办期刊，认可度可想而知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c971931559, createdName=scihappier, createdTime=Tue Sep 19 22:17:00 CST 2017, time=2017-09-19, status=1, ipAttribution=)]

2019-01-25 12078463m83(暂无昵称)

问一下这个杂志的分区是几区，还有以前的clinical andvaccine immunology是三区，但是杂志没有了，改成投在mSphere上，那现在是几区啊？整懵了scihappier 2017-09-19 22:17:00 发表:
美国微生物协会刚创办期刊，认可度可想而知。

scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。

188 0

[GetPortalCommentsPageByObjectIdResponse(id=2118912, encodeId=40cc21189129a, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：传染病 经验分享：审稿人很专业，杂志很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb791638292, createdName=平凡之路, createdTime=Sat Mar 11 11:27:19 CST 2023, time=2023-03-11, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1190756, encodeId=42f51190e56e2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：ASM的期刊，审稿比较快，发表的文章水平不低，编辑负责。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc7f6477604, createdName=ms4000001582217878, createdTime=Mon Feb 07 16:27:18 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106909, encodeId=66591106909f9, content=引言怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106910, encodeId=5eb911069100e, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584870, encodeId=149d5848e05b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投mSphere。去年10月份投出，拒稿，但给大修机会。今年2月10日修改后投出，等待中......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c58d1611556, createdName=liulaoshiyc, createdTime=Mon Feb 17 14:12:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861658, encodeId=daac86165817, content=植物病理学方向，两次小修已中，贴出时间线供大家参考，asm旗下的期刊，对于工作量的要求还是挺高的，偏重微生物方向。 01.29 manuscript submission 01.29 initial qc 01.31 with editor 01.31 reviewing editor assigned 01.31 under review 02.29 minor modifications 04.27 revision received 04.27 initial qc 04.27 with editor 04.30 reviewing editor assigned 04.30 under review 05.22 minor modifications 05.26 revision received 05.26 initial qc 05.26 with editor 05.27 reviewing editor assigned 05.27 under review 06.09 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Jun 09 23:33:54 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576206, encodeId=7f335e620632, content=审稿速度:1.0 经验分享：投稿一个月拒稿但允许重投打算修改后再次重投祝我好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/x3zaA8ibdNOzl5C5ot3vmRP7fhvtMIibLLQ1roy9Vc9rybhichx5Z9ggtuJrtYa7nepc0dhpTibQLo8R55z0T0bEnQ/0, createdBy=985d2236237, createdName=小迎迎, createdTime=Wed Sep 11 00:00:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853511, encodeId=65ce853511f7, content=审稿速度:1.0 经验分享：这个杂志我投过，特点是审稿快，不拖拉。有两种审稿方式，一是直接投，15天左右给审稿结果，如果接收可能会让小修，如果大改或补实验就会先把你据掉，允许再投，同样是15天内给结果。二是，你的手稿已经投过其它杂志，你把其它杂志的审稿意见以及你的修改一起提交，一般5天内好像就能给结果。我是第一种，先是被拒了，要求补数据，及进行修改，补完后又投，15天左右就给就接收了。所以，这个杂志审稿快并不是水，而是加快了审稿速度，节省了作者很多时间。置于质量，msphere 是asm旗下期刊，应该不会错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Sat Aug 31 17:11:46 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566156, encodeId=48cf566156e3, content=问一下这个杂志的分区是几区，还有以前的clinical andvaccine immunology是三区，但是杂志没有了，改成投在mSphere上，那现在是几区啊？整懵了scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, beContent=scihappier 2017-09-19 22:17:00 发表: 美国微生物协会刚创办期刊，认可度可想而知。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52f2182755, createdName=12078463m83(暂无昵称), createdTime=Fri Jan 25 00:00:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547406, encodeId=b1c954e406f2, content=美国微生物协会刚创办期刊，认可度可想而知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c971931559, createdName=scihappier, createdTime=Tue Sep 19 22:17:00 CST 2017, time=2017-09-19, status=1, ipAttribution=)]

2017-09-19 scihappier

美国微生物协会刚创办期刊，认可度可想而知。

248 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务